publication date: Dec. 19, 2010

In this issue: 

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”

Members of Congress say that won’t work.

Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.

After a “humble” start at NCI, von Eschenbach set unachievable goal.

Download (PDF 448KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.